Full article
Taken together with results from large CV outcomes trials of SGLT -2is and GLP -1RAs, combination therapy with these agents potentially provides effective durable glycemic control and CV benefits due to their complementary actions on the defects of T2D.
Summary Upfront combination therapy with both SGLT-2 inhibitors and GLP-1 receptor agonists could further reduce cardiovascular risk in people with type 2 diabetes, although it is crucial to pare down cost and disparities to access to maximise widespread benefits at population level.
Combination Therapy with SGLT2 Inhibitors and GLP
Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors , GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria.
Combination therapy appears well tolerated, with no significant increase in serious adverse events beyond those expected from each agent individually. Conclusions The combination of GLP-1 RAs and SGLT2 inhibitors exerts additive benefits on glycaemic control, body weight, and blood pressure reduction.
A retrospective analysis of combination therapy with GLP
The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: A systematic review and meta-analysis.
In this large real-world cohort, combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with a lower hazard of all-cause mortality, while most secondary cardiorenal outcomes showed generally favourable but imprecise estimates. These findings suggest that sustained concurrent use of …
Efficacy and safety of the combination or monotherapy with GLP
To evaluate the efficacy and safety of combination therapy with sodium-glucose cotransporter2 ( SGLT-2 ) inhibitors and glucagon-like peptide-1 ( GLP-1 ) receptor agonists in the treatment of type 2 diabetes mellitus (T2DM).
Objective To determine whether the combined use of glucagon-like peptide-1 ( GLP-1 ) receptor agonists and sodium-glucose cotransporter-2 ( SGLT-2 ) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual ...
Combining GLP
Drugs that are analogs for native glucagon-like peptide-1 (glucagon-like peptide-1 receptor agonists [ GLP -1RAs]) and those that inhibit sodium-glucose-linked transporters in the kidney (the sodium-glucose cotransporter 2 inhibitor [SGLT2i] drugs) were originally developed to lower glucose in people with type 2 diabetes (T2D). When drugs from both these classes were tested in long-term, large ...
Conclusion: Glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor combination therapy showed superior effects on reducing HbA1c, body weight, FPG, 2 h PG, SBP, BMI and LDL-C, without major safety issues, when compared with monotherapy in patients with type 2 diabetes mellitus.